NCT06490250Recruiting
Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients
Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises on Pulmonary Function, Exercise Capacity and Quality of Life in Patients With Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 15 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study aims to compare the effects of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with hypertrophic cardiomyopathy. By investigating these interventions, the investigators seek to introduce novel approaches that can enhance pulmonary function, exercise capacity, and overall quality of life for these patients. In the study, which will involve three groups-the control group, the inspiratory muscle training (IMT) group, and the Baduanjin group-it was calculated that a total of 51 patients, with 17 in each group (n = 17), should be included. The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other days. The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- First submitted
- 29 Jun 2024
- Start date
- 25 Oct 2024
- Primary completion date
- 30 Jul 2025
- Lead sponsor
- Istanbul University - Cerrahpasa
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06490250
What you commit to
- Study type: Interventional
- Planned participants: 51
- From 25 Oct 2024 to the primary completion date, 30 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute decompensated heart failure
- Unstable angina pectoris
- Significant coronary artery disease (CAD)
- Uncontrolled hypertension (despite medication)
- Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation)
- Severe neurological disorders causing autonomic dysfunction
- Cognitive impairment that prevents communication
Lab values
- Decreased ejection fraction (\<40%)
Other
- Severe renal dysfunction (estimated glomerular filtration rate \<30 mL/min/m²)
- Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems
Who the study is looking for
- Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI
- Clinically and hemodynamically stable (patients with NYHA Class I and II)
- Patients over 18 years of age
- Patients who provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul University-Cerrahpasa (IUC) Cardiology Institute Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.